Clinical Outcomes and Efficacy of Human Epidermal Growth Factor Receptor 2–Targeted Therapy in Breast Cancer With Uncommon In Situ Hybridization Patterns or Discordant Immunohistochemistry
Patients with ASCO/CAP group 4, discordant ISH-/IHC+ results, and weakly amplified group 3 and discordant ISH+/IHC- have low benefit from HER2 therapy, and alternative approaches for such patients are needed.
Authors
- Rita Nanda (ORCID: https://orcid.org/0000-0001-5248-0876)
- Dezheng Huo (ORCID: https://orcid.org/0000-0002-4041-1678)
- Qianchen Zhang
- Frederick M. Howard (ORCID: https://orcid.org/0000-0002-6039-1141)
- Nan Chen (ORCID: https://orcid.org/0000-0001-9938-9957)
- Fangyuan Zhao (ORCID: https://orcid.org/0000-0001-9776-3677)
- Jincong Q. Freeman (ORCID: https://orcid.org/0000-0002-1119-2146)
Institutions
- Chicago Department of Public Health (US)
- University of Chicago (US)
- Applied Mathematics (United States) (US)
- Cancer Genetics (United States) (US)
Publication Details
- Journal
- JCO oncology advances.
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1200/oa.24.00016
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00